ストックスクリーナーアプリを入手
2.98
0.33%
-0.01
アフターアワーズ：
2.98
前日終値:
$2.99
開ける：
$3.02
24時間の取引高:
551.04K
Relative Volume:
1.61
時価総額：
$247.32M
収益：
$351.37M
当期純損益:
$-174.01M
株価収益率:
-1.4396
EPS:
-2.07
ネットキャッシュフロー:
$-126.94M
1週間 パフォーマンス:
+3.11%
1か月 パフォーマンス:
+3.47%
6か月 パフォーマンス:
-9.42%
1年 パフォーマンス:
-22.19%
1日の値動き範囲:
$2.9501
$3.08
1週間の範囲:
$2.825
$3.08
52週間の値動き範囲:
$2.60
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
AVIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
2.98 | 247.32M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times
JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com
Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX
Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News
Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada
Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP
Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz
Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks
Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks
Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire
Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan
Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World
Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN
Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews
Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com
Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener
Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan
HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa
Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com
Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - The Manila Times
Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener
Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire
Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):